Business Wire

EDGE

23.2.2021 17:42:03 CET | Business Wire | Press release

Share
HALCON Unveils UAE’s First Air Defence Missile

HALCON, a regional leader in the production and supply of precision-guided weapons, today unveiled SkyKnight - the first UAE designed and manufactured counter-rocket, artillery, and mortar (C-RAM) missile system, at the International Defence and Exhibition Conference (IDEX) 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005887/en/

EDGE, the parent company of HALCON, has been developing a short-range air defence system, as has Germany-based Rheinmetall AG, which was actively seeking a missile system to form part of its Skynex air defence system. The companies decided to jointly offer a solution, with HALCON providing SkyKnight, the missile system to the highly regarded Oerlikon Skynex Air Defence System, which sets new standards with its unique open architecture.

HALCON’s SkyKnight was purposely designed to counter the full spectrum of modern threats, providing early warning signals and precise surface-to-air intercept capabilities targeting of rotary-wing aircraft, unmanned aerial vehicles (UAVs) rockets, artillery, mortar, and other fixed-wing aircraft at a range of up to 10Km.

Commenting on this landmark international elevation of a UAE-manufactured missile, H.E. Faisal Al Bannai, EDGE Group CEO and Managing Director said: “SkyKnight is the UAE’s first, but will not be the last air defence missile developed by HALCON. We are pleased to team up with Rheinmetall, a leading player in the defence industry, for us to jointly offer the world’s most advanced and comprehensive C-RAM solution leveraging our SkyKnight missile and Rheinmetall’s Skynex solution. This collaboration is a clear message that EDGE is open to teaming up with various players to offer joint advance solutions.”

The Oerlikon Skynex air defence system comprises the Oerlikon Skynex control node, multi-sensor units (MSU) featuring active electronically scanned multi-mode radars (AMMR), multiple 35mm revolver guns RG Mk3 and HALCON’s SkyKnight C-RAM missiles and missile launchers, each of which has a capacity of 60 missiles. HALCON’s C-RAM missile is capable of tracking and neutralising numerous, multi-directional incoming targets at one time, providing protection for static assets, as well as for mobile and mechanised forces. Transportable and mobile, the system can be deployed fixed on land, sea and moving land platform.

Rheinmetall AG, through its Swiss subsidiary, Rheinmetall Air Defence, has deployed the Skyguard system in numerous countries, which can bring down fast, small targets, and is used as the inner tier of layered air defence of vital points and critical military infrastructure. Countries that have rolled out Skyguard systems will ultimately upgrade to Skynex, placing HALCON, its SkyKnight C-RAM missile system, and the UAE at the forefront of air defence system innovation.

HALCON is part of the Missiles & Weapons cluster within EDGE, an advanced technology group for defence that ranks among the top 25 military suppliers in the world.

About EDGE

EDGE is an advanced technology group established to develop agile, bold and disruptive solutions for defence and beyond. Enabling a secure future, it is dedicated to bringing innovative technologies and services to market with greater speed and efficiency. Consolidating over 25 entities and employing more than 13,000 brilliant minds, it offers expertise across five core clusters: Platforms & Systems, Missiles & Weapons, Cyber Defence, Electronic Warfare & Intelligence and Mission Support. Headquartered in Abu Dhabi, United Arab Emirates, EDGE is a catalyst for change – set to revolutionise the industry and change its fundamentals.

For more information, visit edgegroup.ae

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye